Damon Reed and his team at Moffitt Cancer Center are leading a phase II clinical trial investigating evolutionary inspired therapy for treating fusion-positive metastatic rhabdomyosarcoma. This study evaluates four different therapeutic treatments using chemotherapy drugs such as vinorelbine, vincristine sulfate, actinomycin D, and cyclophosphamide to determine the most effective approach in preventing disease progression or recurrence. By leveraging innovative treatment strategies, this research aims to improve outcomes for children facing this aggressive cancer.
We are proud to partner with these exceptional researchers and institutions to make these groundbreaking trials possible. We invite you to explore this page to learn about all the incredible, life-changing research funded by the Live Like Bella Pediatric Cancer Research Initiative, working toward making pediatric cancer a treatable and curable disease.
Keiran Smalley, PhD
Defining and Modeling Pediatric Melanoma Development.
Mihaela Druta
A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with Azacitidine in Patients with Recurrent, Resectable Osteosarcoma.
Jianguo Tao MD, Ph.D.
New Therapeutic Vulnerabilities for Pediatric Burkitt Lymphoma.
Damon Reed MD
Uwe Rix
Characterization of PARP16 as a novel target in Ewing’s sarcoma.
Conor Lynch
Identifying How HDAC Suppression of SLC17A7 Drives Osteosarcoma Progression and Metastasis.
Timothy Shaw
Targeting ER Stress in Pediatric Acute Myeloid Leukemia.
Damon Reed
Feasibility of Generating Novel Translational and Therapeutic Strategies based on a Multicenter, Pediatric and AYA Evolutionary Tumor Board; pedsETB.
Andrew Brohl, MD
Towards targeting the chromosome 19 microRNA cluster in Undifferentiated Embryonal Sarcoma of the Liver.
Andrii Monastyrskyi, PhD
Development of EWS/FLI targeted therapies for Ewing sarcoma.
Jonathan Metts, MD